- Baudax Bio ( NASDAQ: BXRX ) said it started a phase 2 trial to evaluate the safety tolerability and intubation conditions of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery.
- The study will test BX1000 in about 80 adult patients, 18-65 years of age, who undergo elective surgery using total intravenous anesthesia (TIVA) in an outpatient setting.
- The company added that about three to five minutes after induction of anesthesia, the randomized NMB treatment will be administered as an intravenous (IV) bolus.
- "We believe that BX1000, in combination with BX3000 (reversal agent), may permit precise control of the time patients are under neuromuscular paralysis," said Baudax Bio's President and CEO Gerri Henwood.
For further details see:
Baudax starts phase 2 study of BX1000 in patients undergoing surgery